Oppenheimer & Co. Inc. Makes New $1.63 Million Investment in ARK Genomic Revolution ETF $ARKG

Oppenheimer & Co. Inc. acquired a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 30,016 shares of the company’s stock, valued at approximately $1,627,000. Oppenheimer & Co. Inc. owned about 0.07% of ARK Genomic Revolution ETF at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ARKG. Park Avenue Securities LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 3rd quarter worth approximately $336,000. Flagship Harbor Advisors LLC purchased a new position in shares of ARK Genomic Revolution ETF during the third quarter worth $229,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of ARK Genomic Revolution ETF in the third quarter valued at $219,000. Sigma Planning Corp purchased a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter valued at $494,000. Finally, Valley National Advisers Inc. purchased a new position in ARK Genomic Revolution ETF during the 3rd quarter valued at about $304,000.

ARK Genomic Revolution ETF Price Performance

BATS ARKG opened at $51.40 on Monday. The stock has a 50-day moving average of $49.92 and a two-hundred day moving average of $37.37. ARK Genomic Revolution ETF has a 1-year low of $24.60 and a 1-year high of $58.83.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.